When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Intuitive Surgical (ISRG) continues to raise optimism among investors owing to its strength in robotics.
Intuitive Surgical (ISRG) announces the FDA clearance of revised da Vinci Xi and X Labeling on Radical Prostatectomy.
Intuitive Surgical, Inc. (ISRG) reachead $418.15 at the closing of the latest trading day, reflecting a +0.22% change compared to its last close.
Eli Lilly is in a buy zone, while weight-loss drug rival Novo Nordisk just forged a lower entry.
The latest trading day saw Intuitive Surgical, Inc. (ISRG) settling at $403.39, representing a +1.25% change from its previous close.
Intuitive Surgical (ISRG) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
As Intuitive Surgical gets FDA clearance for its next-gen robotic surgery system, ISRG stock teases a new breakout.
While the biotechnology sector may receive most of the attention under the broad healthcare umbrella, investors ought to spare some love for medical technology stocks. The enterprises undergirding these securities offer tremendously positive potential for overall patient outcomes.
Intuitive Surgical (ISRG) shares gain on the back of growth in the da Vinci treatment volume and raised procedure prices.
Intuitive Surgical, Inc. (ISRG) concluded the recent trading session at $404.85, signifying a +1.62% move from its prior day's close.
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.